Item(by='defertoreptar', descendants=None, kids=None, score=None, time=1601906478, title=None, item_type='comment', url=None, parent=24687357, text='Paywalled, but I see it&#x27;s dated 7&#x2F;28, so I&#x27;m guessing it&#x27;s based off this paper <a href="https:&#x2F;&#x2F;jamanetwork.com&#x2F;journals&#x2F;jama&#x2F;fullarticle&#x2F;2768841" rel="nofollow">https:&#x2F;&#x2F;jamanetwork.com&#x2F;journals&#x2F;jama&#x2F;fullarticle&#x2F;2768841</a><p>&gt; Question  What is the discriminative accuracy of plasma phospho-tau217 (P-tau217) for differentiating Alzheimer disease from other neurodegenerative disorders?<p>&gt; Findings  In this cross-sectional study that included 1402 participants from 3 selected cohorts, plasma P-tau217 discriminated Alzheimer disease from other neurodegenerative diseases (area under the receiver operating characteristic curve of 0.89 in a neuropathologically defined cohort and 0.96 in a clinically defined cohort), with performance that was significantly better than established Alzheimer disease plasma- and MRI-based biomarkers but not significantly different from key CSF- or PET-based biomarkers.<p>&gt; Meaning  Although plasma P-tau217 was able to discriminate Alzheimer disease from other neurodegenerative diseases, further research is needed to validate the findings in unselected and diverse populations, optimize the assay, and determine its potential role in clinical care.')